News

January 18, 2019

Lynparza Improves Response Rate in Relapsed BRCA-mutated Advanced OC Patients

News

Results of a Phase 3 clinical trial show that Lynparza (olaparib) tablets met the primary goal of significantly improving the objective response rate, which is the percentage of patients whose cancer shrinks or ... Read more

January 16, 2019

Triple Combination Works Well in Recurrent Ovarian Cancer with Smaller Tumors, Study Shows

News

The size of tumors in patients with recurrent ovarian cancer seems to predict responses to a triple combination treatment composed of IMV‘s lead candidate DPX-Survivac, Incyte’s experimental epacadostat, and low-dose chemotherapy, a Phase ... Read more

January 14, 2019January 15, 2019

Talc May Be Tied to Ovarian Cancer and Serious Lung Problems, Health Canada Warns

News

The Canadian government is warning that exposure of the female genital area to talc-containing products may be associated with ovarian cancer and that inhalation of loose talc powder may lead to potentially serious ... Read more

January 11, 2019

New Steps Through OC Pilot Program Offers Support to Ovarian Cancer Patients and Caregivers

News

Aimed at easing the multifaceted impact of ovarian cancer diagnoses, a new national support initiative called Steps Through OC has unveiled its pilot program for women and their families. Tailored ... Read more

January 9, 2019

4 New Research Grants to Promote Study of Tumor Treating Fields as Cancer Therapy

News

In a collaborative effort to support and advance innovative research on Tumor Treating Fields (TTFields) — a therapy that uses electric fields to promote cell death — the oncology company Novocure and ... Read more

January 7, 2019

BRACAnalysis CDx Approved in US as Companion Diagnostic Test for First-line Lynparza Treatment

News

Myriad Genetics‘ BRACAnalysis CDx has been approved by the U.S. Food and Drug Administration as a companion diagnostic test to identify women with ovarian cancer eligible for first-line maintenance treatment with Lynparza (olaparib). ... Read more

January 4, 2019

Lynparza Approved in U.S. as First-line Maintenance Therapy for BRCA-positive Advanced Ovarian Cancer

News

Women with BRCA-mutated advanced ovarian cancer living in the United States can now receive Lynparza (olaparib), developed by AstraZeneca and Merck, as a maintenance treatment for their partial or complete response to first-line ... Read more

January 3, 2019January 3, 2020

Helomics Starts AI-based Tumor Sequencing Aimed at Predicting OC Treatment Responses

News

Helomics, a subsidiary of Predictive Oncology, has begun sequencing tumor samples as part of its collaboration with UPMC Magee Women’s Hospital. The partners aim to use artificial intelligence (AI) to ... Read more

January 2, 2019

Newk’s Cares Campaign to Battle Ovarian Cancer Enters Fifth Year

News

Hoping to improve the rate of early ovarian cancer diagnoses by supporting early detection through symptom awareness and research funding, Newk’s Cares enters its fifth year having raised more than $970,000 ... Read more